Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 9 Recruiting 8 Withdrawn 4 Unknown 4 Not yet recruiting 3 Completed 3 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3 Sarcoma 2 Thoracic 1 Plasma cell 1 Head & Neck 1 Gynecologic 1 Genitourinary 1 CNS 1

Conditions

Ovarian Neoplasms 1

Interventions

Paclitaxel 69 Carboplatin 66 Cisplatin 36 pembrolizumab 34 Gemcitabine 24 liposomal doxorubicin 23 Cyclophosphamide 23 Topotecan 22 Bevacizumab 20 Taxes 14 Docetaxel 13 niraparib 12 Nivolumab 12 olaparib 10 fludarabine 10 Doxorubicin 9 Surveys and Questionnaires 8 Radiotherapy 8 Oxaliplatin 8 aldesleukin 7 Filgrastim 7 rucaparib 6 oregovomab 6 fludarabine phosphate 6 durvalumab 6 avelumab 6 Interleukin-2 6 Hyperthermic Intraperitoneal Chemotherapy 6 Fluorodeoxyglucose F18 6 Cytoreduction Surgical Procedures 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × dostarlimab × Gynecologic × Clear all

NCT03955471 2022-09-10

MOONSTONE

Tesaro, Inc.

Phase 2 Terminated

41 enrolled 22 charts

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡